Osteopore is a Singapore headquartered corporation strategically poised to be a leading medical device company in the region.

We are involved in designing, developing and marketing bioresorbable polymer implants for neurosurgical, orthopedic, and maxillofacial surgery use.

Our proprietary technologies allow for the development of biostructures which are synthetic biologically active tissue engineered products for the restoration of the human skeleton.

Clinical trials for the tissue engineered product, which works by providing a scaffold for the patient’s own bone cells to be regenerated, have been successful.

History of Development

Osteopore platform technology started development in 1996, acquiring extensive engineering and clinical experience.

Feb 2019

US FDA GMP Inspection

Successful inspection by US FDA inspector at our JTC MedTech Hub manufacturing facility


Osteopore Manufacturing Process

Upgraded to ISO 13485 Medical Device Regulation


Osteopore Manufacturing Process

Achieved the Korea GMP in 2016


CE Mark Approval

CE Mark Approval for Osteoplug™ for burr hole cover, and Osteomesh™ for orbital floor reconstruction


Osteopore Manufacturing Process

Achieved the ISO 13485 certification


US FDA 510(k)

US FDA 510(k) cleared for bone void filler for craniofacial application

Nov 2003

Founding of Osteopore

Osteopore International Pte Ltd was founded to commercialised 3D printed scaffold technology to facilitate the adoption of Tissue Engineering and Regenerative Medicine in clinical treatment



First-in-Human for 3D printed burr hole cover


Research Initiation

The founders initiate development of 3D printed scaffold with bioresorbable material